[ Pharmaceutical Sciences Asia - ONLINE ]
E-ISSN 2586-8470
[ Journal Abbreviation: Pharm.Sci.Asia ]
Mahidol University Journal of Pharmaceutical Sciences
  FORMER NAME   "Mahidol University Journal of Pharmaceutical Sciences" Published Since 1974


DOI: 10.29090/psa.2021.05.20.144Pharm Sci Asia 2021; 48(5), 413-419

Efficacy of rosuvastatin and atorvastatin in Vietnamese patients with acute coronary syndrome: A randomized trial

An Viet Tran1*, Thanh Truong Nguyen2, Lien Nguyen Thao Tran1, Phuong Minh Nguyen1, Thang Nguyen3

1 Faculty of Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam
2 Soc Trang General Hospital, Soc Trang Province, Vietnam
3 Faculty of Pharmacy, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam

High-intensity statins have been recommended to initiate in patients after acute coronary syndrome (ACS) to reduce the risk of death and recurrent cardiovascular events. There have been few studies comparing the effectiveness of high-intensity statins in Vietnam. Therefore, we conducted a randomized controlled trial to compare the effects of rosuvastatin versus atorvastatin in Vietnamese patients with ACS. A total of 96 ACS patients were randomized into 2 groups at a ratio of 1:1 to receive rosuvastatin 20 mg/day or atorvastatin 40 mg/day in addition to the standard treatment of ACS. LDL-c and hs-CRP levels were measured before and after the intervention for analysis. No significant differences were found between the two groups at baseline. LDL-c levels were significantly reduced from baseline to 4-day in both groups (p<0.001 in both groups), but the difference in LDL-c levels at 4-day between the groups was not statistically significant (p=0.251). hs-CRP did not increase significantly in the rosuvastatin group but significantly in the atorvastatin group (p=0.209 and p<0.001, respectively). hs-CRP at 4-day was not significantly different between the two groups (p=0.250). The proportion of LDL <1.8 mmol/L after 4 days in the rosuvastatin group was significantly higher than that of the atorvastatin group (OR=4.592; 95% CI 1.365-15.449; p=0.014). There was no significant difference in the LDL-c reduction ≥50% and hs-CRP ≤3 mg/L at 4-day between two groups. In conclusion, rosuvastatin is more effective than atorvastatin in achieving LDL-c targets of <1.8 mmol/L after 4 days in Vietnamese patients with ACS.


Acute coronary syndrome, Atorvastatin, High-sensitivity C-reactive protein (hs-CRP), Low-density lipoprotein cholesterol (LDL-c), Rosuvastatin.

Download full paper (PDF File size: 1,305.75 KB.)

November-December 2021

See other volume


September - October 2021

See other volume


July - August 2021

See other volume


May - June 2021

See other volume


March - April 2021

See other volume


January - February 2021

See other volume


Aims and Scope
Editorial Board
Publication Ethics
Instruction to Authors
All Volumes & Issues
Submit Online
Contact us
Faculty of Pharmacy Mahidol University
Mahidol University
Member's menu

You're now loging on with following account:
Guest (unknown)

Please Sign in or Register

Pharmaceutical Sciences Asia by Faculty of Pharmacy, Mahidol University, Thailand is licensed under CC BY-NC-ND 4.0

    Copyright © 2017-2024
    Faculty of Pharmacy, Mahidol University, THAILAND

We use Cookies

This site uses cookies to personalise your experience and analyse site traffic. By Clicking ACCEPT or continuing to browse the site you are agreeing to our use of cookies.